Ocrevus (ocrelizumab) carries a list price of roughly $67,000 per year, making it one of the most expensive multiple sclerosis treatments on the market. Several factors drive that price tag, from the complexity of manufacturing a biologic drug to the enormous cost of clinical development and the unique market position Ocrevus holds as the only approved treatment for primary progressive MS.
Biologics Cost More to Make Than Pills
Ocrevus is a humanized monoclonal antibody, which means it’s a large, complex protein grown inside living cells rather than synthesized through chemical reactions like a standard pill. Manufacturing biologics requires specialized facilities with strict environmental controls, contamination prevention systems, and climate-regulated production areas. The process involves two major phases: cell culture and harvest, where living cells produce the antibody, followed by purification and modification, where the raw product is refined into a usable drug.
Quality testing alone is far more involved than for conventional drugs. Each batch of Ocrevus must pass multiple biological assays to confirm it works correctly. One test measures the drug’s ability to destroy B cells (the immune cells it targets) using human complement proteins. Another uses natural killer cells to verify the drug triggers the right immune response against its target. These aren’t simple chemical purity checks. They require maintaining live human cell lines and running complex experiments on every production run. That level of quality control adds significant cost at every stage.
Clinical Trials Spanned Thousands of Patients
Bringing Ocrevus to market required three large international trials. The OPERA I and OPERA II trials enrolled a combined 1,656 patients with relapsing MS across more than 300 trial sites in dozens of countries, tracking outcomes over 96 weeks. The ORATORIO trial, which tested the drug in primary progressive MS, enrolled 725 patients. Running trials of this scale, with sites spread across 32 countries and years of patient monitoring, costs hundreds of millions of dollars before the drug earns a single dollar in revenue.
Pharmaceutical companies typically factor these development costs into their pricing, spreading the investment across the expected years of market exclusivity. For a drug targeting a relatively small patient population (about one million people in the U.S. have MS, and only a fraction use any single treatment), the per-patient cost of recouping that investment is naturally higher than it would be for a drug treating a condition affecting tens of millions.
No Real Competition for Progressive MS
One of the biggest pricing factors is market position. When Ocrevus launched in 2017, it became the first and only FDA-approved treatment for primary progressive MS, a form of the disease that had no approved therapies. That distinction gives Roche, the company behind Ocrevus through its subsidiary Genentech, significant pricing power. There’s no generic or biosimilar alternative, and patients with primary progressive MS have no comparable option to switch to if the price is too high.
For relapsing MS, Ocrevus does compete with other disease-modifying therapies, but it demonstrated strong results in head-to-head trials, which has made it a preferred choice for many neurologists. High demand with limited competition is a classic recipe for premium pricing.
The “Value-Based” Pricing Argument
Roche justifies Ocrevus pricing partly through economic modeling that estimates the broader savings the drug creates. A study presented at ISPOR (an international health economics conference) estimated that treating primary progressive MS patients with Ocrevus instead of best supportive care saved the Canadian healthcare system an estimated 61.3 million Canadian dollars over five years. Those savings came from reduced healthcare visits and hospitalizations (about $33 million), lower productivity losses from disability ($14 million), and reduced need for informal caregiving ($11 million).
The logic is that by slowing disability progression, Ocrevus keeps patients out of wheelchairs, out of nursing facilities, and in the workforce longer. Each of those outcomes reduces costs elsewhere in the system. Whether that justification fully accounts for a $67,000 annual price is debatable, but it’s the framework drugmakers use to defend high price tags for treatments that prevent expensive long-term disability.
Infusion Costs Add to the Total
The list price doesn’t capture everything you actually pay. Ocrevus is given as an intravenous infusion, typically twice a year after the initial doses. Each session requires a medical facility, nursing staff, monitoring equipment, and pre-medications to reduce infusion reactions. These facility and administration fees vary widely depending on whether you receive the infusion at a hospital outpatient center, a standalone infusion clinic, or a doctor’s office, but they can add hundreds to thousands of dollars per session on top of the drug’s cost.
What Patients Actually Pay
The $67,000 list price is what manufacturers charge before insurance negotiations, rebates, and discounts. Most patients with commercial insurance pay significantly less out of pocket, though co-pays for specialty drugs can still run into thousands of dollars annually. Genentech offers a co-pay assistance program for commercially insured patients, though specific savings depend on your plan and coverage tier.
For uninsured or underinsured patients, Genentech runs a patient foundation that provides Ocrevus at no cost to those who qualify financially. The foundation uses an income-based eligibility tool rather than publishing fixed thresholds, so you’d need to check directly through their website or by calling their specialist line at (888) 941-3331 to find out if you qualify. Several independent nonprofit foundations also offer grants to help cover MS treatment costs.
The gap between list price and what insurers actually pay after rebates is substantial for most specialty drugs, but exact net prices aren’t publicly disclosed. What’s clear is that the sticker price reflects a combination of genuine manufacturing complexity, development costs, and the market leverage that comes with being the only option for a serious, progressive disease.